VantroMarket Overview
← All markets
Health Market Overview

Belgium

Last updated: November 2026
Regulatory Body
Federal Agency for Medicines and Health Products (Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten / Agence Fédérale des Médicaments et des Produits de Santé - FAMHP/AFMPS)
Typical Timeline
60-210 days depending on product type and review pathway
Regulatory Overview

The Federal Agency for Medicines and Health Products (FAMHP/AFMPS) is the primary national authority responsible for ensuring the quality, safety, efficacy, and availability of medicines, medical devices, diagnostics, and digital health products in Belgium. The agency operates under the framework of the Law of 25 March 1964 on Medicines and subsequent amendments, as well as directly applicable EU regulations including EU MDR 2017/745 for medical devices and EU IVDR 2017/746 for in vitro diagnostics. For pharmaceuticals, Belgium participates fully in the European Medicines Agency (EMA) centralized procedure, mutual recognition procedures (MRP), and decentralized procedures (DCP), meaning that many marketing authorizations are granted at the EU level with FAMHP serving as the national competent authority for purely nationally authorized products.

Submission requirements vary by product category but generally follow EU harmonized standards. Pharmaceutical dossiers must be compiled in Common Technical Document (CTD) format and submitted via the relevant EU procedure or nationally through FAMHP for specific product types. Medical devices and IVDs must bear CE marking from a designated Notified Body before being placed on the Belgian market, in accordance with EU MDR and IVDR requirements. A local authorized representative or Belgian establishment is required for manufacturers based outside the European Economic Area. Belgium has actively aligned with recent EU reforms including the European Health Data Space initiative, increasing acceptance of real-world evidence for digital health solutions, and strengthened post-market surveillance obligations introduced under MDR and IVDR transition timelines.

Procurement Overview

Belgium operates a predominantly public healthcare system funded through a combination of social security contributions and government budgets, with procurement of health products governed at both the federal and regional levels. The Institut National d'Assurance Maladie-Invalidité (INAMI/RIZIV), the National Institute for Health and Disability Insurance, plays a central role in determining reimbursement eligibility and conditions for pharmaceuticals, medical devices, and diagnostics. Public hospital procurement is conducted through individual institutions or purchasing groups and must comply with the Law of 17 June 2016 on Public Procurement, which transposes EU procurement directives. Federal-level tendering for certain strategic health products, including vaccines and critical medicines, is coordinated through the Federal Public Service Health, Food Chain Safety and Environment (SPF Santé Publique/FOD Volksgezondheid), often in collaboration with INAMI/RIZIV and regional health authorities in Flanders, Wallonia, and the Brussels-Capital Region.

Belgium's private healthcare sector is well-developed, with private hospitals, pharmacies, and diagnostic laboratories representing significant procurement channels alongside public institutions. Unlike lower-income markets, Belgium does not rely on donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi, as it is a high-income donor country rather than a recipient. However, Belgian entities including the Belgian Development Cooperation (Enabel) and academic medical centers are active participants in international health initiatives. Belgium does not impose explicit local manufacturing preference policies under national law, operating instead within the EU single market framework; however, recent European Industrial Strategy discussions and the Strategic Autonomy agenda have prompted increased interest in nearshoring and supporting European manufacturing capacity for critical health products, which may indirectly influence future procurement priorities.

Go deeper

This is a generic market overview. For a structured entry brief tailored to your product category, including regulatory pathway, pricing, and risk assessment, use the Market Brief tool.

Generate a free Market Brief for Belgium →
Market overview generated by AI and updated monthly. Verify with in-country regulatory authorities before making market entry decisions.